Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

TARKINAID · Targeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases

FP7Status: CLOSED1 January 201231 December 2015EU funding €2,999,860

The project aims to develop novel inhibitors of chronic autoimmune and inflammatory diseases by targeting members of the Src tyrosine kinase family. Src-family kinases have recently emerged as major therapeutic targets in malignant diseases but their suitability as potential targets of inflammatory diseases has not yet recieved widespread acceptance. On the other hand, members of the applicant consortium have recently obtained genetic evidence showing that myeloid Src-family kinases (Hck, Fgr and Lyn) are indispensable for murine models of autoimmune inflammatory diseases such as rheumatoid arthritis or blistering skin diseases. They also developed a number of novel Src-family kinase inhibitors that also block inflammation-related in vitro leukocyte functions. The applicants will test and further develop novel Src-family kinase inhibitors as anti-inflammatory compounds, using several in vitro and in vivo inflammation assays to optimize the structure of the selected molecules. They will also test whether Src-family inhibitors already in clinical use in oncology patients also inhibit inflammatory processes. Finally, they will use Src-family kinase-deficient mice in several inflammation models to test the role of those kinases in more detail and to provide further reference information for the consortium's preclinical drug development activity. The selected inhibitors and mutant mice will be pre-screened using various inflammation-related in vitro leukocyte functions and short-term in vivo inflammation models, and then analyzed in detail using a number of in vivo mouse models of chronic autoimmune and inflammatory diseases. The project is expected to result in development of novel preclinical drug candidates against chronic autoimmune and inflammatory disease with novel mechanism of action, as well as novel knowledge on the role of Src-family kinases in inflammatory diseases. The project will be performed in close cooperation between European and Brazilian scientists.

Consortium · 11 organisations

coordinator

SEMMELWEIS EGYETEM

HU · €551,962

participant

UNIVERSITA DEGLI STUDI DI VERONA

IT · €296,082

participant

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

DE · €493,280

participant

UNIVERSIDADE FEDERAL DO RIO DE JANEIRO

BR · €246,822

participant

BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS

EL · €177,570

participant

VICHEM CHEMIE KUTATO KORLATOLT FELELOSSEGU TARSASAG

HU · €296,010

participant

FUNDACAO OSWALDO CRUZ

BR · €147,978

participant

ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU

IT · €100,000

participant

UNIVERSITAETSKLINIKUM FREIBURG

DE · €246,228

participant

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR · €295,950

participant

AMBIOTIS

FR · €147,978

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.